Tissue Heart Valve Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Stented, Stentless, and 1 Other Tissue Heart Valve

Global Tissue Heart Valve Market Report to 2032

The global tissue heart valve market was valued at $1.8 billion in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.1%, reaching $1.9 billion by 2032.

This report covers the global market for tissue heart valves, including stented, stentless, and sutureless tissue heart valves used in surgical valve replacement procedures.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by continued preference for tissue valves, improved tissue valve durability, and adoption of stentless and sutureless technologies. However, improvements in mechanical valves and the expansion of transcatheter aortic valve implantation are expected to limit stronger growth.

Market Overview

The global tissue heart valve market includes bioprosthetic valves used to replace diseased or damaged heart valves. These products are commonly used in patients who require valve replacement but prefer to avoid lifelong anticoagulation therapy.

The market includes stented, stentless, and sutureless tissue heart valves. Stented tissue valves remain widely used because of their established clinical history and familiarity among surgeons. Stentless and sutureless options are gaining attention because they may improve blood flow performance and reduce operative time.

Tissue heart valves are often preferred over mechanical valves because they more closely mimic natural valve function and are more biocompatible. This makes them an attractive option for many patients, especially older adults.

Increased adoption of sutureless and stentless tissue valves is supporting market growth. These technologies help address some limitations of traditional stented valves by improving hemodynamic performance and reducing procedural complexity. Their use is contributing positively to overall tissue valve utilization.

Market Drivers

Preference for Tissue Valves

The main driver of the tissue heart valve market is the continued preference for tissue valves over mechanical options. Tissue valves are more biocompatible and mimic the natural heart valve more closely than mechanical valves.

Mechanical valves can trigger immune response issues and increase the risk of blood clot formation. Because of this, patients who receive mechanical valves require lifelong anticoagulation therapy.

Patients who receive tissue valves generally do not require lifelong anticoagulation therapy. This is an important benefit for both surgeons and patients, especially when balancing long-term safety, lifestyle impact, and monitoring requirements. As a result, tissue valves have continued to cannibalize the mechanical valve market.

Improved Durability

Mechanical valves are more durable than tissue valves, but tissue valve durability has improved over time due to better processing methods and product technology.

Tissue valves now typically last 10 to 15 years on average. Many valves have also been shown to remain functional for 20 years, depending on the patient and product.

Because the largest patient demographic for tissue valves is the 65 and older age group, a 10 to 15-year lifespan is often sufficient for the implanted valve to last for the remainder of the patient's life. As durability continues to improve, tissue valves may become suitable for progressively younger patients, expanding the eligible treatment population.

Stentless Tissue Valves

Stentless tissue valves are often preferred over stented tissue valves in certain cases. The stent mounting used in stented valves can limit blood flow through the valve, particularly for patients who need smaller valve sizes.

The main advantage of a stentless valve is its wider valve opening, which allows blood to flow more freely and more naturally. This can improve hemodynamic performance and reduce mechanical stress on the valve and surrounding heart tissue.

Reduced stress may also support longer valve durability. Special tissue treatments are intended to make stentless valves more durable, and long-term data may show that these products last longer than stented valves on average.

Market Limiters

Improvements in Mechanical Valves

Improvements in mechanical heart valve technology are expected to limit the tissue heart valve market. Mechanical valves already offer high levels of durability, which remains their main advantage over tissue valves.

Materials used in mechanical valve production are expected to continue improving. Ideally, these improvements will reduce clot formation and allow mechanical valves to be used more often with less need for anticoagulation therapy.

If mechanical valves become safer and require less intensive anticoagulant management, they could regain appeal among patients and surgeons. This would limit the rate at which tissue valves continue to take share from mechanical valve products.

Transcatheter Aortic Valve Implantation

Transcatheter aortic valve implantation is a major limiter for traditional surgical tissue heart valves. Open surgery remains a common approach for treating aortic stenosis, but TAVI procedures are rapidly taking market share.

TAVI devices are currently approved for inoperable, high-risk, and intermediate-risk patients. As these procedures become more widely adopted, they reduce the number of patients treated with surgical tissue heart valve replacement.

The approval and expansion of TAVI into lower-risk patient groups will have a further cannibalizing effect on traditional tissue valves used in surgery. This is expected to remain one of the most important pressures on the market over the forecast period.

Slow Market Growth

The global tissue heart valve market is expected to grow at a modest CAGR of 1.1% through 2032. While tissue valves remain clinically important, the market is mature and faces pressure from competing treatment options.

Growth is supported by improved durability, patient preference, and specialized valve designs. However, these positive factors are moderated by the shift toward transcatheter treatment and continued improvements in competing technologies.

As a result, suppliers must focus on product refinement, surgeon confidence, durability data, and global access to maintain stable performance in a slow-growth market.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers tissue heart valves used in surgical heart valve replacement procedures, including stented, stentless, and sutureless tissue heart valves.

Markets Covered and Segmentation

Tissue Heart Valve Market

• Device type: Stented, stentless, and sutureless heart valves.

Stented tissue heart valves are widely used surgical bioprosthetic valves supported by a frame. These products remain important because of their long clinical history, established surgeon familiarity, and broad availability across global markets.

Stentless tissue heart valves are designed without a supporting stent structure. This allows for a wider valve opening and can support more natural blood flow, particularly in patients requiring smaller valve sizes.

Sutureless tissue heart valves are designed to reduce implantation time and simplify surgical workflow. These products can help shorten operative times and may support adoption in cases where procedural efficiency is important.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how valve type, durability, surgical preference, patient selection, and competing transcatheter options are shaping the global tissue heart valve market.

Competitive Analysis

Edwards Lifesciences was the leader of the global tissue heart valve market in 2025. The company offers its Carpentier-Edwards(R) line of surgical heart valves, with aortic tissue valve products offered through the PERIMOUNT(R) portfolio.

Edwards Lifesciences benefits from a strong global presence, an established product line, and long-standing physician familiarity. These factors are expected to help the company maintain its market share over the forecast period.

Medtronic was the second-leading competitor in the global tissue heart valve market. Its product portfolio includes the Hancock(TM), Mosaic(TM), Avalus(TM), and additional surgical valve lines. The Hancock(TM) and Mosaic(TM) stented tissue heart valves are used for both aortic and mitral valve replacement.

Medtronic launched Avalus Ultra(TM), its next-generation surgical aortic tissue valve, in the U.S. in April 2024. This was followed by a commercial rollout in Western Europe in October 2024 and a launch in India in October 2025. This phased expansion shows Medtronic's strategy to broaden access to advanced tissue valve technologies.

Abbott was the third-leading competitor globally in 2025. Its tissue valve portfolio is centered on the Epic(TM) mitral and aortic stented tissue valves after the withdrawal of the Trifecta(TM) valve in 2023 due to early structural valve deterioration reports. This has weakened Abbott's position, especially in North America, and the company is not expected to gain significant share amid strong competition from Edwards Lifesciences, Medtronic, and Corcym.

Technology and Practice Trends

Sutureless Valve Adoption

Sutureless tissue valves are gaining attention because they can reduce operative time and simplify implantation. This is important in cardiac surgery, where shorter procedure times can support workflow efficiency and reduce time under anesthesia.

These devices are expected to remain an important area of product development.

Stentless Valve Performance

Stentless tissue valves can improve hemodynamic performance by allowing a wider valve opening and more natural blood flow.

This design is especially useful for patients who require smaller valve sizes, where stented designs may restrict flow.

Improved Tissue Processing

Advances in tissue processing are helping improve valve durability. Better durability makes tissue valves more attractive to patients and physicians, especially as the expected functional life of these products increases.

As durability improves, tissue valves may be considered for younger patient groups over time.

Reduced Need for Anticoagulation

Avoiding lifelong anticoagulation remains one of the strongest advantages of tissue valves. This benefit supports patient preference and helps distinguish tissue valves from mechanical options.

The ability to reduce long-term medication burden is especially important for older patients.

Surgical Valve Competition from TAVI

TAVI continues to reshape the valve replacement landscape. As transcatheter technologies expand into broader patient groups, traditional surgical tissue valves face competitive pressure.

This trend is especially important in aortic valve replacement.

Global Product Expansion

Leading companies are expanding tissue valve availability across major regions. Medtronic's Avalus Ultra(TM) launch sequence across the U.S., Western Europe, and India reflects a broader push to increase access to newer surgical valve technologies.

Global distribution and surgeon adoption will remain important competitive factors.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global tissue heart valve market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• Which tissue valve types are shaping market demand?
• How do stented, stentless, and sutureless tissue valves compare in adoption and growth?
• Why do surgeons and patients often prefer tissue valves over mechanical valves?
• How is improved durability expanding the potential patient population for tissue valves?
• What role do stentless valves play in improving blood flow and long-term performance?
• How is TAVI affecting demand for traditional surgical tissue valve replacement?
• Which companies lead the global tissue heart valve market?
• How are Edwards Lifesciences, Medtronic, and Abbott positioned in the competitive landscape?

The Global Tissue Heart Valve Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand surgical valve trends, and support commercial planning in the global tissue heart valve market.